June 2023 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
August 2025 in “JAAD International” Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
64 citations
,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
December 2024 in “International Journal of Drug Delivery Technology” The new delivery method for dutasteride is more effective and has fewer side effects.
42 citations
,
July 2015 in “Drug Development and Industrial Pharmacy” Flutamide, delivered by solid lipid nanoparticles, could potentially treat hair loss.
72 citations
,
June 1979 in “Biochemical Society Transactions” Flutamide and its metabolite can effectively reduce androgen effects.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
32 citations
,
November 1996 in “International Journal of Dermatology” Antiandrogens can help treat skin conditions like acne and excessive hair in women when used carefully.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
April 2022 in “Reactions Weekly”
March 2025 in “JAAD reviews.” Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
1 citations
,
January 2010 in “Endocrine abstracts”
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
20 citations
,
May 2011 in “Cancer Biology & Therapy” Finasteride may improve prostate cancer treatment outcomes.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.